Several Phase II trials for BKM120 are currently recruiting patients with recurrent glioblastoma, metastatic renal cell carcinoma, metastatic castration-resistant prostate cancer, metastatic non-small-cell lung cancer, and HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.